I'm positive that you right when you say that GK gave his all in the quest to do the very best for Novogen and its shareholders.
In that light it is almost inconceivable that he would have left the company of his own accord. I won't list again all that he did for the company that was just a shell when he brought the Triaxial technology into Novogen.
If he did indeed leave with reluctance it is surely equally inconceivable that he would just lay down and retire.
Having been diagnosed with a potentially fatal form of prostate cancer at the time he left Novogen Mark 1 he obviously left no stone unturned to come up with an effective treatment for himself. In that quest he obviously succeeded which turned out to be very good for the fortunes of the Novogen Mark 2 shareholders (because he was still alive)... Not to mention literally life-changing for himself and his family.
Ok... So last year he found himself on the outside looking for a new project to Persue. What better than to start again and work up a commercial way to leverage the technology and technique he had used to save his own life in those years he was in the wilderness and away from Novogen Mark 1? In that space of exactly one year he has formed a new company and taken it public on the ASX with an IPO.
Now a word about the new company. You have done your usual very detailed trawl back through the record . I congratulate you for that talent, especially as I often don't have the time to always do the same and have to rely on my long memory of the events and the timescale.
With all that I have said above is it even conceivable that GK would have gone ahead with this new project if he wasn't pretty damn sure that he would be able protect the position with a strong set of intellectual property? To be able patent it in other words.
It must be equally obvious that if phenoxodiol ultimately failed in a phase 3 trial after more than 400 patients had taken the drug... then in those "wilderness years"... and with an added incentive I thankfully only have to imagine... he pulled out every stop to find a cure for himself after failing on the conventional available therapies of the time.
No. He had obviously found a new effective way to use idronoxil (phenoxodiol) and in doing so had to discover what they call in the patent business..... an inventive step. I believe that is correct. And I believe it to be a new formulation that allows the active ingredient to bypass the oral problem of having the liver discard and expel the majority of the drug from the body before it can do its work at the site of the tumour.
To go ahead with an IPO he must also have satisfied the ASX among others that this was a viable business with the necessary qualifications to list publicly.
I feel he is definitely onto something, and that it is able to be patent protected. I also think that it won't impinge on the way that the SBPs and the ATM technologies will perform. I can only look backward and ponder on how much more we would know by now on the progress of Novogen where he still the CEO. But we all are where we are any amount of coulda-woulda-shoulda will not be very productive. I'm still as firm on Novogen as I ever was. I just wish that someone would just tell us all something..... anything..... please!!!
Apples
NRT Price at posting:
10.5¢ Sentiment: None Disclosure: Held
